

Subject Index

- Abl-gene 65, 81
Acute leukemia (AL) 3, 256
-, cytogenetical characteristic 56
Acute lymphoblastic leukemia (ALL) 4, 11, 28, 65, 80, 101
-, prognosis 32
-, survival of 30
-, bone marrow autografts in 5
-, remission 28
-, relapse 29
Acute myeloid leukemia (AML) 3, 22, 81, 163, 166
Acute nonlymphoid leukemia (ANLL) 8, 22, 62, 101, see also AML
Adhesive interactions 93, 132
AIDS XLVII, LXXXIII
-, mechanisms of CD4⁺ T-cell depletion in LXX
-, therapy XXIV, LXXXIII, 140
Autocrine receptor activation XXVII
AZT (3'-Azido-2',3'-dideoxythymidine)
-, pharmacokinetics of LXXXV
-, clinical application of LXXXVII
- BCR gene XLIV, 65, 81
B-cell chronic lymphocytic leukemia (B-CLL) XLII, 38
B-cell hairy cell leukemia (B-HCL) 38
B-cell transformation XLV
Blast cell 72
-, clonality 33
Blast colony-forming cell (B1-CFC) 93
BFM-protocol 28
BFU-E 13, 106, 203
Bone marrow
-, fibroblasts of 101
-, stromal cells of 93, 97, 101
Bone marrow transplantation (BMT) 3, 16, 67, 78
Breakpoint
-, the location of XLI, XLII
- Ceataea letifera
-, conditioned medium 110
Cell adhesion molecule (CAM) 94
- Cell line
-, FD/MAC 115
-, HL-60 110
-, K-562 256
-, 32D 191
CD44 glycoprotein 125
CFU-GM 14, 50, 79, 106, 111, 203
CFU-mix 106
CFU-S 106
Chemotherapy 3
Chromatin 72
Chromosome
-, abnormalities 59
-, rearrangements XL
-, translocations XL
-, 7q deletion 60
-, 5q deletion 59, 166
-, 1p deletion 241
-, 11q 23 breakpoint XLI
-, 19q 13 breakpoint XLII
-, yeast artificial (YAC) XLI
Chronic lymphocytic leukemia (CLL)
see also B-CLL
-, cytogenetical characteristics of XLIII
Chronic myeloid leukemia (CML) XLIV, 56, 81, 93, 101, 256
Chronic myelomonocytic leukemia (CMML) 60
-, production of IL-1 23
Colony-stimulating factor (CSF) 83, 115
see also G-CSF, GM-CSF, M-CSF
Conditioned medium
-, by stromal cells 101
-, by Ceataea letifera 110
Cystic fibrosis (CF) 194
Cytosine arabinoside 72
Cytokine receptor 188, 302
- Dexter culture 97
Dideoxynucleosides LXXXIII
-, clinical research of LXXXIV
Differentiation 110
Down syndrome 33
- Erythropoietin (Epo) 187, 203
Evolution 316

- Fibroblasts 83, 101, 157
- Gene
 -, BCL-3 XLIII
 -, BCR XLIV, 65, 81
 -, c-fms 116, 192
 -, c-raf 1 208
 -, cloning 153, 159
 -, DDC (deleted in colorectal carcinomas) XLI
 -, erb-B 213
 -, expression 175
 -, for CD 10 XLV
 -, for CD 34 153
 -, for IL-2 294
 -, for IL-3 166
 -, for IL-4 166
 -, for IL-5 166
 -, for M-CSF 116
 -, HLA LXXIII, 290
 -, H-ras 1 262
 -, MHC LXXIII, 176, 267, 286, 311
 -, -, class II LXVII
 -, regulation 87
 -, tax LIII, 235
 -, therapy LXXIX
 -, TNF 175
 -, transfection 79
 -, tumor suppressor XLIV, 213, 241
 -, rex LV
 -, for IL-3 receptor 185
 Glycophosphatidylinositol (GPI) anchors 286
 G-CSF 16, 191
 GM-CSF 78, 97, 115, 159
 Graft rejection 268
 Granulocytes 86, 128
- Hemopoiesis 77
 Hematopoietic progenitors 14, 50, 79, 106, 111, 203
 -, immortalization of 204
 HIV XLVIII, LXXXIII, LXXXIV, 140, 235
 Human herpes virus 6 (HHV 6) 251
 Human β -globin gene cluster CV
 Human retroviruses
 -, tumorigenesis of LXIV
 HTLV-1 L, 235
 -, long terminal repeat (HTLV-LTR) 251
 HTLV-II LIII
- IFN-gamma LXXVII, 97, 111
 Immunoinhibition LXXIV
 Immunological disease LXX
 Immunotherapy LXXVIII
 IL-1
 -, production 23, 41, 268
- IL-2 LXXVIII, 111, 187
 -, production 50, 268, 294
 IL-3 12, 36, 78, 115, 166, 191, 203
 IL-4 166, 187, 268
 IL-5 166, 268
 IL-6 36
- Kaposi's sarcoma LXII
 Karyotypic instability 58
- Laser irradiation 72
 Leukemic cells
 -, proliferation of 14
 Lymphocytes 86
 Lymphokine
 -, treatment with LXXVII
- Macrophages 86, 131
 M-CSF (CSF-1) 115, 191
 Mast cells 129, 185
 Mesenchymal cells LXV, 83
 Melanoma 214
 Minimal residual disease (MRD) 65
 Molecular cloning 166, 186
 Monoclonal antibodies
 -, treatment with XXVII
 Monocytes 131
 Mouse embryogenesis 106
 Multigene families 316
 Multiple myeloma (MM)
 -, cell morphology 41, 50
 -, prognostic factor 41
 Muramyl peptides' (MPs) 290
 Mutations
 -, in CF gene 194
 Myelodysplasia 59
 Myelodysplastic syndrome (MDS) 22, 101
 Myeloproliferative leukemia virus 201
- Natural killer cell (NK-cell) 42, 127, 267
 Neuroblastoma
 -, prognosis 241
 NF-kB site 295
 Nonlymphocytic leukemia (NLL) 22
- Oncogene
 -, amplification of 241
 -, H-ras I 262
 -, Abl 65, 81
 -, N-myc 241
 -, c-fms 116, 192
 -, c-raf 1, 208
 -, MYCN 242
 -, p53 81, 164

- Philadelphia translocation 65
 Platelets 130
 Polymerase chain reaction (PCR) 65, 175,
 194, 260
 Preleukemia (PL) 56
 "Price of cure" 7
 Proteoglycans (PGs) 121

 Raus sarcoma virus (RSV)
 -, transformed cell line 260
 -, integration of 260
 Recessive oncogene 163
 Receptor
 -, for epidermal growth factor (EGF) XXIII,
 185, 191, 214
 -, for erythropoietin (Epo) 205, 302
 -, for G-CSF 302
 -, for GM-CSF 159
 -, for IL-1 302
 -, for IL-2 205, 302
 -, for IL-3 185, 205
 -, for IL-4 205, 302
 -, for IL-6 205, 302
 -, for IL-7 205, 302
 -, for platelet-derived growth factor (PDGF)
 XXIII, 191, 302
 -, soluble 302
 -, for TNF 302
 -, for prolactin 302
 Refractory anemia (RA) 23, 60
 Retroviral element S71 256
 Retroviruses XLVIII
 Reverse transcriptase (RT) LIX, LXXXIV
 Rheumatoid arthritis LXXIII

 Secondary leukemia 56
 Severe congenital neutropenia (SCN)
 -, treatment of 16
 Sex chromosome 163
 Sickle cell disease CX
 Single-stranded conformation polymorphism
 (SSCP) 194
 Stromal layer 94, 97
 Suppressor gene 264
 -, tumor XLIV, 213, 241

 T-cell 311
 -, activation of 11, 286
 -, receptor gene 65
 T-lymphocyte 126, 286, 294
 Thalassemias C
 Thujapolysaccharides (TPSg) 140
 TNF-alpha 111, 175, 290
 -, production 50
 TNF-beta 175
 Transient myeloproliferative disorder 33
 TUM-antigens 279
 Transformed pigment cells (Tr melanophores)
 213

 Virus
 -, Raus sarcoma 260
 -, myeloproliferative leukemia 201

 Yeast artificial chromosome (YAC) XLI
 Yolk sac (YS) 106